DDrare: Database of Drug Development for Rare Diseases

Secukinumab 150 mg provided in 1.0 ml pre-filled syringes (pfss) for sc injection. (DrugBank: Secukinumab)

告示番号	疾患名（ページ内リンク）	臨床試験数
271	強直性脊椎炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02750592 (ClinicalTrials.gov)	March 22, 2016	4/4/2016	Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis	An Open-label, Phase III, Study of Subcutaneous Secukinumab to Assess Efficacy, Safety and Tolerability at up to 52 Weeks in Japanese Patients With Active Ankylosing Spondylitis	Ankylosing Spondylitis	Drug: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.	Novartis Pharmaceuticals	NULL	Completed	18 Years	N/A	All	30	Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02750592
(ClinicalTrials.gov)

March 22, 2016

4/4/2016

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

An Open-label, Phase III, Study of Subcutaneous Secukinumab to Assess Efficacy, Safety and Tolerability at up to 52 Weeks in Japanese Patients With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Drug: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

Novartis Pharmaceuticals

NULL

Completed

18 Years

N/A

All

Phase 3

Japan